Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7039087 | 0.86 | ALDH1A1 (0.43) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| SCHEMBL4842427 | 0.86 | PTGER3 (0.52) | ALDH1A1GAAGFERLMNAHTT | |
| SCHEMBL6561819 | 0.85 | S1PR2 (0.43) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| SCHEMBL9307489 | 0.85 | S1PR1 (0.57) | — | |
| SCHEMBL4837941 | 0.84 | MAPT (0.53) | ALDH1A1GAAGFERLMNA | |
| SCHEMBL926240 | 0.84 | KDM1A (0.47) | ALDH1A1GAALMNA | |
| SCHEMBL1039522 | 0.83 | HTT (0.51) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| SCHEMBL1901206 | 0.81 | S1PR5 (0.55) | ALDH1A1LMNAHTT | |
| SCHEMBL30639470 | 0.78 | ALDH1A1 (0.56) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| SCHEMBL1717077 | 0.78 | ALDH1A1 (0.56) | ALDH1A1GAAGFERCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102746214-A | Novel indoline compounds | FOURNIER LAB SA | 2012-10-24 | — | — | CN | disclosed |
| CN-102321020-A | The lxr receptor regulator | FOURNIER LAB SA | 2012-01-18 | — | — | CN | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| CN-101184731-A | Indoline compounds | FOURNIER LAB SA (FR) | 2008-05-21 | — | — | CN | disclosed |
| CN-1950340-A | LXR receptor modulators | FOURNIER LAB SA (FR) | 2007-04-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | ALDH1A1 1819/4885GAA 1612/4885GFER 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.